eISSN: 1731-2531
ISSN: 1642-5758
Anaesthesiology Intensive Therapy
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

vol. 53
Original paper

The diagnostic and prognostic value of mature and total adrenomedullin for sepsis: a prospective observational study

Tetsu Yonaha
Toyoaki Maruta
Go Otao
Koji Igarashi
Sayaka Nagata
Takeshi Yano
Masahiko Taniguchi
Kazuo Kitamura
Isao Tsuneyoshi

Departments of Anesthesiology and Intensive Care Unit, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
Research and Development Management, Bioscience Division, TOSOH Corporation, Kanagawa, Japan
Circulatory and Body Fluid Regulation, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
Anaesthesiol Intensive Ther 2021; 53, 5: 411–417
Online publish date: 2021/12/30
Article file
- The diagnostic.pdf  [0.14 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Adrenomedullin (AM) is a potent vasodilator peptide that was first identified in extracts of human pheochromocytoma [1]. To date, it is known to be synthesised in several organs and tissues, including the heart, lungs, kidneys, adipose tissue, and vascular endothelium [2]. AM affects the physiological functions of the cardiovascular system, kidneys, and central nervous system. It regulates blood pressure and vascular tone, increases cardiac output, and promotes diuresis and natriuresis [1–5]. Kitamura et al. [6, 7] were the first to report that two major molecular forms of AM circulate in the human blood, namely the biologically active mature AM (mature AM) form with an amidated C-terminus, and an inactive intermediate AM with a non-amidated C-terminal glycine. Although it is assumed that mature AM might be the key peptide with the AM function, circulating mature AM is quickly degraded and cleared from the circulation and is difficult to detect using a standard immunoassay because of the masking effect of its binding protein (complement factor H) [8]. The mid-regional AM (MR-proAM or proAM), which is the inactive fragment of AM, is more stable than mature AM and is used to predict the levels of mature AM [9]. In clinical settings, MR-proAM has been identified to be closely associated with the sequential organ failure assessment (SOFA) or acute physiology and chronic health evaluation (APACHE) II scores, and can be useful as a diagnostic and prognostic biomarker for sepsis [9–18]. Recently, a double monoclonal sandwich immunoassay was developed that can also measure bioactive mature AM, which is called bio-ADM [15, 19]. Several investigators have indicated that the levels of mature AM could serve as a useful and objective biomarker to predict severity, organ failure, and mortality in patients with sepsis [10, 20]. However, further evaluation is required for the clinical use of mature AM as a reliable biomarker of sepsis [8]. Therefore, in this study, we aimed to obtain additional information about mature AM, including its efficacy and the validation of the optimal cut-off, to help in its development as a marker of sepsis.


Study protocol

This prospective, observational, single-centre study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Hospital Ethical Committee for Human Studies (Ref: 0-0317) on December 1, 2014, and retrospectively registered with the Japanese Clinical Trial Registry UMIN-CTR (Ref: UMIN000036474). General or written informed consent was obtained from all patients (age ≥ 20 years). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed in the preparation of this manuscript. For analysis, patients were enrolled upon admission to the intensive care unit (ICU) and diagnosed with sepsis or not according to the Sepsis-3 definitions, and then retrospectively categorised into non-sepsis or sepsis groups [21]. Exclusion criteria were age < 20 years, pregnancy, trauma, postoperative patients, or lack of informed consent.

Data collection

Clinical data obtained from electronic medical records included the first diagnosis, chronic comorbidities, laboratory test results, microbiology, and biomarker levels on admission to the ICU. Blood samples were collected for measuring the levels of AM peptides on ICU admission (day 1) and post-ICU admission day 3. The blood samples were collected into tubes containing 1.0 mg mL–1 EDTA-2Na and were split into small aliquots to avoid repeated freezing and thawing. The aliquoted samples were frozen as quickly as possible and stored at –70°C until use. AM is derived from an AM precursor via a two-step enzymatic reaction. First, a 185-amino acid AM precursor, known as preproadrenomedullin, is converted to glycine-extended AM, which is the 53-amino acid, inactive, intermediate form of AM (intermediate AM). Subsequently, by enzymatic amidation, intermediate AM is converted to mature AM, a 52-amino acid peptide with an amide group at the C-terminus [6, 7]. Because conventional assays cannot distinguish between intermediate and mature AM forms, AM sometimes indicates total AM, which is the sum of the levels of intermediate and mature forms. In our study, plasma levels of both mature and total AM were measured by a specific fluorescence immunoassay (Tosoh Corporation, Tokyo, Japan) using two independent antibodies – one that binds to the ringed structure was used for the total AM assay, and the other that binds to the middle region between the ring and the C-terminal portion of the peptide was used for the mature AM assay, as described previously [22, 23]. Plasma presepsin (PSEP) levels were measured with a rapid chemiluminescent enzyme immunoassay (CLEIA) using a PATHFAST immunoanalyser (Mitsubishi Chemical Medience, Tokyo, Japan). Additionally, we obtained data on procalcitonin (PCT), white blood cells (WBCs), C-reactive protein (CRP), lactate, platelets, and creatinine, which were clinically measured in serum samples at the central laboratory of the University of Miyazaki Hospital.


The primary outcome of the study was the diagnostic performance of biomarkers and SOFA score on ICU admission for sepsis. Secondary outcomes were the time course of AM levels and the prognostic performance of biomarkers and SOFA score for sepsis.

Statistical analysis

Statistical analysis was performed using MedCalc 17 (MedCalc Software Bvba, Ostend, Belgium) or JMP 15 (SAS Institute Inc., Cary, NC, USA). Data are expressed as median (IQR: interquartile range) or exact numbers. Categorical data were examined using the chi-square or Fisher’s exact test. Continuous variables were compared using the Mann-Whitney U or Kruskal-Wallis test, as appropriate. Pearson product- moment correlation coefficient was used to measure the strength of the relationship between two variables. Receiver operating characteristic (ROC) analysis and comparison of the area under the curve (AUC) were performed to evaluate the accuracy of the biomarkers in diagnosing and predicting sepsis. A value of P < 0.01 was considered statistically significant.


Diagnosis of sepsis on ICU admission

Ninety-eight patients were enrolled in this study between January 2015 and November 2018 (Table 1). A total of 56 patients were diagnosed with sepsis according to the Sepsis-3 definitions, and 42 were not diagnosed with sepsis. The abdomen and respiratory tract were the most common sites of infection in patients with sepsis. The most common reason for admitting patients with no sepsis to the ICU was heart failure, followed by acute pancreatitis, gastrointestinal bleeding, aortic disorders, interstitial pneumonia, and autoimmune diseases, among others. We could not track the outcome for one patient with sepsis who was transferred to another hospital. The levels of AM peptides, values of clinical parameters including laboratory results, and SOFA score on ICU admission are presented in Table 2. The levels of mature AM, total AM, PCT, and PSEP were substantially higher in patients with sepsis than in those without sepsis on day 1 (Figure 1 and Table 2). However, these significant differences in the levels of both AM peptides disappeared on day 3 (Figure 1). To compare the diagnostic accuracy of sepsis using each biomarker, we performed an ROC analysis and determined the AUCs using the values obtained for the 98 patients on ICU admission (Table 3). The AUCs of mature and total AM were 0.848 and 0.879, respectively, indicating that both AM peptides exhibit significant predictive values for the diagnosis of sepsis, in comparison with other biomarkers, such as PCT, PSEP, SOFA score, and lactate levels (0.828, 0.682, 0.772, and 0.660, respectively). The cut-off levels of mature and total AM for the diagnosis of sepsis were 5.2 pmol L-1 (≈ 31.2 pg mL–1) and 48.3 pmol L–1 (≈ 289.8 pg mL–1), respectively (Table 3). Significant correlations between the levels of mature and total AM were found in blood samples obtained from the same patients on days 1 and 3 (Figure 2).
The 28-day mortality rates in patients without or with sepsis were 14.3% and 30.9%, respectively (Table 1). In patients with sepsis, the levels of mature and total AM were not statistically significant on day 1; however, they were significantly increased in non-survivors on day 3 compared with the levels in survivors (Figure 3). Likewise, the AUCs of these AM peptides for predicting the 28-day mortality rates in patients with sepsis became significant on day 3, but not on day 1 (Table 4). The cut-off levels of mature and total AM for the 28-day mortality on day 3 were 5.4 pmol L–1 (≈ 32.4 pg mL–1) and 72.5 pmol L–1 (≈ 435.0 pg mL–1), respectively (Table 4).


In this study, we found that the plasma levels of mature and total AM on day 1 of ICU admission in patients with sepsis were significantly higher than those in patients without sepsis. The good correlation between the plasma levels of both peptides observed in the present study demonstrates that both total and mature AM are equally useful in diagnosing sepsis based on the latest Sepsis-3 definitions. In contrast, with regards to the clinical outcome in patients with sepsis, a significant difference in the level of each AM was found between survivors and non-survivors 3 days after admission. In addition, the levels of both AM forms could predict the 28-day mortality in patients with sepsis on day 3, but not on day 1. Therefore, unlike in previous studies, we found that it may take several days for these AM peptides to prognosticate the 28-day mortality in patients with sepsis because AM levels increased even in patients with a good prognosis on day 1.
In some previous studies, the levels of total AM were assessed and their utility in diagnosing sepsis was compared with that of other chemical biomarkers, such as CRP, PCT, lactate, and PSEP [8, 9, 18, 20, 24–26]. We found that among all the clinical parameters examined, the diagnostic accuracy for sepsis on the first day of ICU admission was the highest for total AM, and that of mature AM was the second highest. It is assumed that mature AM is biologically active, and would thus be a more informative biomarker than total AM in patients with sepsis. In our study, the cut-off level of mature AM for the diagnosis of sepsis was approximately 31.2 pg mL–1, and its AUC was 0.848, with a sensitivity of 88.1% and a specificity of 67.9%. Other investigators have also reported that the ability of mature AM to identify patients with sepsis was modest because an AUC of 0.76 and a Youden’s index derived cut-off of 37 pg mL–1 generated a sensitivity of 61% and a specificity of 80% [20]. These cut-off values of mature AM were similar, indicating that values of about 30 pg mL–1 could be applicable to diagnose sepsis, which is a novel finding on mature AM. The half-life of mature AM in plasma is approximately 20 min. As a biomarker of acute cardiovascular failure, the levels of mature AM can change significantly during the first 24 h after diagnosis [10]. Indeed, in our study, the levels of mature AM in patients with sepsis significantly increased on day 1 but reverted to the same levels as in patients without sepsis 3 days after admission, indicating that the time frame in which sepsis can be identified by this peptide may be confined to an early stage after the onset.
Accumulating evidence indicates that clinical outcome in patients with sepsis can be determined based on AM levels [10–12, 14–17]. However, investigators have pointed to the need for more data to evaluate the mortality rate in patients with sepsis prognosticated by the levels of mature AM [8]. Marino et al. [15] found that the levels of mature AM at ICU admission strongly correlated with the 28-day mortality rate in patients with sepsis. Patients with AM levels > 70 ng L–1 had a 28-day survival rate of 55%. Recent evidence supports this result. Kim et al. [10] reported that the cut-off value of mature AM levels for 28-day mortality was 97.12 pg mL–1. However, in the present study, the levels of total and mature AM on day 1 could not be used to predict the 28-day sepsis-related mortality. It is well known that AM levels are elevated in patients with heart failure, myocardial infarction, pulmonary hypertension, SIRS, inflammatory bowel disease, and renal failure, but this does not necessarily correlate with prognosis [2, 27–30]. Therefore, even patients with sepsis who have a good prognosis may have elevated AM levels early in the course of sepsis. This may explain the results presented in Figure 3, showing no significant difference in the levels of mature and total AM between non-survivors and survivors on ICU admission (day 1) when multidisciplinary treatment had not yet been initiated. We found that the levels of mature and total AM on day 3 in patients with sepsis had a high predictive value for sepsis-related mortality as determined by ROC analysis. Interestingly, Mebazaa et al. [11] reported that in patients with mature AM levels > 70 pg mL–1 on admission, a decrease in the levels below 70 pg mL–1 on day 2 was associated with the recovery of organ function on day 7 and a better 28-day outcome (9.5% mortality), whereas persistently elevated levels of mature AM on day 2 were associated with prolonged organ dysfunction and high 28-day mortality (38.1% mortality). These results suggest that the levels of mature AM may remain high if treatment is unsuccessful and organ damage continues in sepsis. Indeed, as demonstrated in Figure 3, the sustained increase in the levels of mature AM in patients with sepsis correlated with worsening prognosis.
In the present study, the cut-off levels of mature and total AM on day 3 for the diagnosis of the 28-day sepsis-related mortality were approximately 32.4 and 435.0 pg mL–1, respectively. The cut-off level of mature AM was lower than that in previous studies (30 pg mL–1 vs. 70 pg mL–1). This could be explained by the sensitivity of the assay used in each study, indicating that the cut-off values obtained by different assay methods may be different. Recently, Lundberg et al. [20] reported a Youden’s index cut-off of 45 pg mL–1 for predicting the 28-day sepsis-related mortality in their sepsis cohort, which was as low as that in the present study. It has been presumed that total AM represents the sum of synthesised intermediate AM and mature AM. However, little is known about the ratio of each peptide in total AM. We suspected that if the composition ratio varied for each patient with sepsis, the levels of total AM might not directly reflect the functional status of mature AM [31]. However, as discussed previously, we found a definite correlation between the levels of mature and total AM, both of which were measured from an identical blood sample, with a resultant increase in a similar fashion. Based on our results, it may be sufficient to measure either mature or total AM for the diagnosis of sepsis.

Limitations of the study

This study has some limitations. First, this study was performed as a small, single-centre study focusing on the diagnostic performance of AM for sepsis and septic shock based on the Sepsis-3 definitions. Given the similarities in responses and outcomes, further studies with a much larger patient sample size and multi-centre design are required. Second, as discussed previously, the AM-binding protein, complement factor H, hinders the reliable measurement of mature AM [9, 18, 32]; this technical difficulty in the assay precludes its practical use. Recently, Weber et al. [19] reported a new assay to reliably measure the bioactive AM using a double monoclonal sandwich immunoassay that can measure C-terminally amidated biologically active AM. We used our originally developed assay for measuring mature AM and found that the limits of detection and quantitation were 0.133 and 0.085 pmol L–1, respectively, according to the Clinical and Laboratory Standards Institute (CLSI) protocols. The intra- and inter-assay coefficients of variation were 1.8% and 5.1%, respectively [23]. Thus, we believe that our assay is as reliable as the one reported by Weber et al. Third, we do not provide any evidence of whether AM might resolve or worsen the septic state itself. Although the effects of AM or AM antibody therapy for sepsis have been evaluated in some preclinical animal studies [33], it is still unclear whether AM will have beneficial therapeutic effects in patients with sepsis. There is an ongoing, multi-centre study evaluating AM-binding antibody therapy for sepsis (AdrenOSS-2) [34]. The results of this study might eventually be useful in characterising the efficacy of AM therapy in patients with sepsis.


We conclude that (1) at the early onset of sepsis, both mature and total AM are excellent biomarkers with the highest diagnostic accuracy for sepsis among the biomarkers that we evaluated; (2) a good correlation exists between each AM, indicating that the changes in the plasma levels may directly reflect one another; and (3) both AM peptides have the potential to predict the 28-day mortality in patients with sepsis several days after the onset. Further studies are required to clarify the relationship between mature AM and its clinical significance in comparison with total AM.


1. The authors would like to thank Mariko Tokashiki, Noriko Hidaka, Mio Kurogi, and Toshiko Watanabe for their technical advice and assistance in data collection. We also thank Editage (www.editage.com) for English language editing.
2. Conflicts of interest: Koji Igarashi is an employee of Tosoh Corporation. The other authors declare no competing interests.
3. Financial support and sponsorship: This study was supported by a grant for clinical research from the University of Miyazaki Hospital.
4. Presentation: This study was posted to the preprint server “Research Square”, which can be accessed at https://www.researchsquare.com/article/rs- 10485/v2.


1. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560. doi: 10.1006/bbrc.1993.1451.
2. Kato J, Kitamura K. Bench-to-bedside pharmacology of adrenomedullin. Eur J Pharmacol 2015; 764: 140-148. doi: 10.1016/j.ejphar. 2015.06.061.
3. Ebara T, Miura K, Okumura M, et al. Effect of adrenomedullin on renal hemodynamics and functions in dogs. Eur J Pharmacol 1994; 263: 69-73. doi: 10.1016/0014-2999(94)90524-x.
4. Yamaguchi T, Baba K, Doi Y, Yano K. Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. Life Sci 1995; 56: 379-387. doi: 10.1016/0024-3205(94)00903-1.
5. Fukuhara M, Tsuchihashi T, Abe I, Fujishima M. Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. Am J Physiol 1995; 269: R1289-1293. doi: 10.1152/ajpregu.1995.269.5.R1289.
6. Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993; 194: 720-725. doi: 10.1006/bbrc.1993.1881.
7. Kitamura K, Kato J, Kawamoto M, et al. The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma. Biochem Biophys Res Commun 1998; 244: 551-555. doi: 10.1006/bbrc.1998.8310.
8. Kim MH, Choi JH. An update on sepsis biomarkers. Infect Chemother 2020; 52: 1-18. doi: 10.3947/ic.2020.52.1.1.
9. Önal U, Valenzuela-Sánchez F, Vandana KE, Rello J. Mid-regional pro-adrenomedullin (MR-proADM) as a biomarker for sepsis and septic shock: narrative review. Healthcare (Basel) 2018; 6: 110. doi: 10.3390/healthcare6030110.
10. Kim H, Hur M, Struck J, Bergmann A, Di Somma S. Circulating biologically active adrenomedullin predicts organ failure and mortality in sepsis. Ann Lab Med 2019; 39: 454-463. doi: 10.3343/alm.2019.39.5.454.
11. Mebazaa A, Geven C, Hollinger A, et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care 2018; 22: 354. doi: 10.1186/s13054-018-2243-2.
12. Caironi P, Latini R, Struck J, et al. Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis. Chest 2017; 152: 312-320. doi: 10.1016/ j.chest.2017.03.035.
13. Gonzalez Del Castillo J, Wilson DC, Clemente-Callejo C, et al. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission. Crit Care 2019; 23: 335. doi: 10.1186/s13054-019-2613-4.
14. Saeed K, Wilson DC, Bloos F, et al. The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study. Crit Care 2019; 23: 40. doi: 10.1186/s13054-019-2329-5.
15. Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. Crit Care 2014; 18: R34. doi: 10.1186/cc13731.
16. Chen YX, Li CS. The predictive value of adrenomedullin for development of severe sepsis and septic shock in emergency department. Biomed Res Int 2013; 2013: 960101. doi: 10.1155/2013/960101.
17. Chen YX, Li CS. Prognostic value of adrenomedullin in septic patients in the ED. Am J Emerg Med 2013; 31: 1017-1021. doi: 10.1016/j.ajem.2013.03.017.
18. Bernal-Morell E, García-Villalba E, Vera MDC, et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Infect 2018; 76: 249-257. doi: 10.1016/j.jinf.2017.12.003.
19. Weber J, Sachse J, Bergmann S, Sparwaßer A, Struck J, Bergmann A. Sandwich immunoassay for bioactive plasma adrenomedullin. J Appl Lab Med 2017; 2: 222-233. doi: 10.1373/jalm.2017.023655.
20. Lundberg OHM, Lengquist M, Spångfors M, et al. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care 2020; 24: 636. doi: 10.1186/s13054-020-03351-1.
21. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-810. doi: 10.1001/jama.2016.0287.
22. Nomura I, Kato J, Tokashiki M, Kitamura K. Increased plasma levels of the mature and intermediate forms of adrenomedullin in obesity. Regul Pept 2009; 158: 127-131. doi: 10.1016/j.regpep.2009.08.003.
23. Kawano S, Kawagoe Y, Kuwasako K, et al. Gender-related alterations in plasma adrenomedullin level and its correlation with body weight gain. Endocr Connect 2015; 4: 43-49. doi: 10.1530/EC-14-0131.
24. Bernal-Morell E, García-Villalba E, Vera MDC, et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Infect 2018; 76: 249-257. doi: 10.1016/j.jinf.2017.12.003.
25. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 426-435. doi: 10.1016/S1473-3099 (12)70323-7.
26. Kondo Y, Umemura Y, Hayashida K, Hara Y, Aihara M, Yamakawa K. Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis. J Intensive Care 2019; 7: 22. doi: 10.1186/s40560-019-0374-4.
27. Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJV. The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 2004; 103: 179-201. doi: 10.1016/j.pharmthera.2004. 07.002.
28. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem 2007; 14: 1689-1699. doi: 10.2174/092986707780830943.
29. Yuyun MF, Narayan HK, Ng LL. Prognostic significance of adrenomedullin in patients with heart failure and with myocardial infarction. Am J Cardiol 2015; 115: 986-991. doi: 10.1016/j.amjcard. 2015.01.027.
30. Self WH, Storrow AB, Hartmann O, et al. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med 2016; 34: 257-262. doi: 10.1016/j.ajem.2015.10.033.
31. Cao, YN, Kitamura K, Ito K, et al. Glycine-extended adrenomedullin exerts vasodilator effect through amidation in the rat aorta. Regul Pept 2003; 113: 109-114. doi: 10.1016/s0167-0115(03)00002-8.
32. Di Somma S, Magrini L, Travaglino F, et al. Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med 2013; 51: 1167-1175. doi: 10.1515/cclm-2012-0795.
33. Geven C, Kox M, Pickkers P. Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front Immunol 2018; 9: 292. doi: 10.3389/fimmu.2018.00292.
34. Geven C, Blet A, Kox M, et al. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). BMJ Open 2019; 9: e024475. doi: 10.1136/bmjopen-2018-024475.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.